Shanghai Institute Of Biological Products
38
11
11
22
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 38 trials
100.0%
+13.5% vs industry average
29%
11 trials in Phase 3/4
0%
0 of 22 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (38)
Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term Infants
Role: lead
Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
Role: lead
Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above
Role: lead
A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above
Role: lead
A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout.
Role: lead
Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months
Role: lead
A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
Role: lead
A Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects.
Role: lead
A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients.
Role: lead
A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals
Role: lead
A Clinical Trial of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
Role: lead
A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.
Role: lead
Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo
Role: lead
A Clinical Trial of SIBP-A16 Injection in Healthy Adults
Role: lead
A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine
Role: lead
A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.
Role: lead
A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine
Role: lead
A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine
Role: lead
A Clinical Trial of A Quadrivalent Influenza Vaccine
Role: lead
Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old
Role: lead